CJC-1295 vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
A long-acting GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation for days with single injection.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CJC-1295 | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | CJC-1295 DAC contains a reactive linker that binds to albumin after injection. This extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 8-12 weeks typical |
| Best Time to Take | Before bed | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show sustained elevation of GH and IGF-1 levels. Research demonstrates 2-10 fold increase in GH levels depending on dose and formulation. Combination with GHRP produces synergistic GH release greater than either alone. | Studies show sustained 2-10 fold increase in GH levels lasting several days. Single weekly injection maintains elevated IGF-1. Less physiologic than pulsatile protocols but more convenient. |
Frequently Asked Questions: CJC-1295 vs CJC-1295 DAC
What is the difference between CJC-1295 and CJC-1295 DAC?
CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. CJC-1295 DAC is a growth hormone peptide that a long-acting ghrh analog with drug affinity complex for extended half-life. provides sustained gh elevation for days with single injection. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of CJC-1295 and CJC-1295 DAC is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.